Professor Anthony Dayan introduced the meeting, which was aimed at increasing understanding of the ways in which scientific ideas could be developed and exploited by industry. He pointed out that for many years there had been a tradition oflinks between the academic community and the pharmaceutical industry, but there were now opportunities for similar cooperation in other areas. He hoped that this meeting would facilitate this process by permitting an exchange of information on what was needed, where the opportunities were, and how they could best be exploited.
Mr L Jenkins (Wellcome Research Laboratories, Beckenham) explained how an idea could be developed for commercial exploitation by the pharmaceutical industry. He stressed that the development of any idea would take time, and that the chances of financial success with any one product were usually small. As an example he pointed out that a newly synthesized compound had about a 1:10 000 chance of reaching the market place. Any idea was likely to take between 5 and 20 years to pass through the necessary development stages, including the required toxicity testing.
Funding for the development of a product could come from a variety of sources including Government, the City, contract houses or small businesses using venture capital. Laboratory and human resources and appropriate scientific and business expertise was necessary to ensure that the many pitfalls were avoided. At the end of all this, and usually following expenditure of several million pounds, a dossier of data on a new pharmaceutical product on the safety, efflcacy and quality ofthe product had to be submitted to the licensing authority. Once licensed the product still needed to be marketed successfully. Even then, once in clinical use it could turn out to be less effective than anticipated, and so fail to capture its predicted market-share and therefore fail to produce the expected return on the investment.
Mr Jenkins said there were several pitfalls that university departments had to be aware of if they wished to develop a discovery commercially. The academic's natural impulse to tell everyone about an exciting new discovery had to be curbed if the idea was to be developed as a commercial proposition. Once a discovery had been published, then intellectual property rights could not be established for the discovery. If there were none then it would not be worth investing in. Even a presentation in a closed meeting, or on a poster, would seriously undermine any chance of establishing intellectual property rights to a discovery, so a department that was serious about developing potentially commercial ideas needed to develop established procedures for its personnel to follow.
Intellectual property rights might be established by obtaining copyright on material, or by establishing the discovery as industrial property. This could be done by patenting the discovery, or by a variety of other routes. Patenting was not always the best option, for example monoclonal antibodies were not adequately protected by a patent, and better protected by making them a trade secret.
To patent a discovery, Mr Jenkins explained, one needed a full description of the invention which was then filed in the Patent Office. The idea, concept, material, substance or process must be new, not obvious and industrially applicable. Patents were only effective nationally and therefore had to be filed separately in all countries ofinterest. They prevented exploitation by others for a limited period only. In effect, the Patent Office restricts exploitation by others in return for public disclosure Biology'. He pointed out that industry had now moved on from the 'molecular roulette' approach which was an almost purely chemical approach with very little biological input, and rudimentary toxicity testing, to a more sophisticated strategy in which an attempt was made to correlate biological activity and chemical structure, and where animal models were used to predict biological function, both at the development stage and during more thorough toxicity testing. Large industrial organizations now tended to concentrate on developing pharmaceuticals affecting different organs or biological systems rather than trying to cover the entire biological spectrum, and the major advance usually comes from the biologist who has characterized a receptor or a way of blocking a receptor; the chemist's input is usually secondary to these biological advances. This exposed the great need for suitable models, e.g. for multiple sclerosis and a number of other chronic diseases, to permit such fundamental work on mechanisms.
Dr Cavalla went on to explain that the impact of biotechnology on these areas was difficult to predict.
The number of biotechnology scientists required might not be as great as many people thought. There were fiequently problems in patenting these biological agents, which were often naturally occurring substances. The complex molecules that could be made by genetic engineering were rarely orally active, and therefore there was frequently only a limited market for them. There were also problems in toxicity testing, which remained to be resolved. A recent innovation is the setting up of a number of 'Club' schemes. These consist of 3 or 4 companies and a similar number of university departments.
Clubs for protein engineering, recombinant DNA technology and animal cell biotechnology exist. A relatively small amount of money is involved, the majority being put up by SERC. The idea is to provide a forum for discussion of ideas of mutual interest and a way to interchange expertise. The clubs have so far been very successful in establishing links between the universities and industry.
Dr I Fleming (Department of Trade and Industry (DTI) Biotechnology Division) then spoke about his Department's efforts to encourage industry to collaborate nationally and internationally, especially on long-term and strategic research. In particular the DTI was trying to improve links in less obvious areas such as environmental protection and electronics. Effort was directed via three main routes: LINK, collaborative clubs and EUREKA.
LINK was a UK initiative whereby a number of companies are associated with one or more research units to encourage exploitation ofnew technology and to give academic benefits in the form of access to information and funding. It was hoped that this initiative would generate about £420 million of research funding, mostly from industry and from successful exploitation of discoveries.
One LINK scheme was the 'gene plan tool kit' collaborative venture, which involved 11 companies, 2 universities and 2 research council units, and is developing gene products for marketing. Other areas where similar collaborations are underway are in developing genetically engineered enzymes for the brewing industry from yeast, in drug delivery and targeting, in biotransformation, protein engineering, cell recognition, food technology and plant sciences.
The club projects are on a smaller scale and are aimed at helping smaller companies to keep abreast of new developments in specific fields. They are also intended to encourage sharing of risks and development costs. DTI sponsor about 100 such clubs, usually based on a single topic, such as 'The use of biocatalysts', 'The use of immobilized cells', ' The development of alternative toxicity methods', 'ATP and DNA probe technologies'. The DTI usually provides 50% ofthe necessary funding for these clubs, and the rest comes from industry.
EUREKA is a collaborative research initiative between the 12 European Community (EC) countries, the 6 European Free Trade Association (EFTA) countries and Turkey. A company has to identify a topic and then seek partners in other countries in taking the project forward. Ministers agree funding of projects at meetings held at 9-monthly intervals. The programme is designed to encourage cooperation and development on an international basis. It is very well thought of on the Continent. Unfortunately, at present there are only 5 UK-led projects being funded under the scheme.
Once the product has been developed then there may still be considerable problems in exploiting the idea. The DTI is also trying to reduce any hindrances to exploitation wherever possible. Three possible 'bottle-necks' have been identified: (i) the regulatory climate; (ii) public perceptions; and (iii) a lack of awareness of skills. DTI tries to encourage regulations that do not inhibit innovation or stifle new developments, while of course maintaining adequate safeguards, e.g. in the formulation of guidelines for the release of genetically engineered material into the environment.
In the context of public perception the DTI is concerned that the glamour and pull of genetic engineering may lead to shortages of necessary specialists in other fields. They plan to do a survey of attitudes before considering whether any public education programme is necessary in this area.
To try to deal with the development of appropriate skills a Centre for the Exploitation of Science and Technology (CEST) has been set up as an independent body to identify and exploit new areas. This receives £1 million from the Department of Trade and Industry, Department of Education and Science and the Cabinet Office and is also supported by 18 industrial companies. It is hoped that more will alsojoin. There are also a number of other services, such as the National Advisory Service and the National Centre for Schools Biotechnology aimed at increasing public awareness and education in the areas of interest to industry.
Mr D Baily (Hall Hambrecht & Quist) then spoke about using venture capital to develop a product. The first requirement was a good product that had been shown to work and that had an identified and appropriate market niche; for example, Neurosciences Ltd was a new company set up to develop and market a portable EEG machine plus associated computing facilities to enable the electrical activity of the brain to be visualized and interpreted as maps rather than viewed as recordings from pairs of electrodes.
He explained that it is important to understand what venture capital was. It was for short-term projects, not for developments that were likely to take 5-20 years. The idea was to use the money to take a developed product or company up to the stage at which it was of interest to larger commercial bodies, e.g. by way of a take-over. The project was recognized to be high risk, but was attractive because of the possibility of a high return on the capital if successful. It was not a loan or an overdraft facility, and the investors would expect to be part of the development team and to be closely involved in the development. Usually the project would run as an unlisted company, and the venture capitalist would seek to free his money at the end by gaining a listing for the company on the Stock Exchange.
The research worker wishing to develop a product this way should realize that the aim is quite clearly to make money, the venture capitalist is not a charity and will expect the development to proceed in a business-like fashion. The management team will be critical to the success ofthe project. Since all ventures run into problems, it is important to have a resourceful team with good management expertise that will be able to deal with problems positively and effectively when they arise.
In general, the speakers felt that UK management was second to none and had plenty of entrepreneurial spirit if it was only left unfettered by external controls.
Dr G J Turnbull (Pharmaceutical Proteins Ltd) then spoke about his experience starting up a biosciences company to market protein products (such as Factor IX) excreted in the milk oftransgenic sheep. The initial research had been carried out by AFRC scientists interested in improving breeds of sheep. The spin-off was the possibility of using the sheep to produce a range of protein pharmaceutical products in their milk, an easily harvested product.
He also stressed the fact that the aim was to make money, and the importance ofa good management team and a flexible approach to the inevitable problems that were arising. He also emphasized the importance of sorting out the legal and financial aspects of the venture at an early stage. He particularly stressed the need for staying power and lots of enthusiasm if one were to succeed. In general he felt that development was best left to the experts, that research workers tended not to transplant well into the management field and needed to recognize that they would have to take a back seat during the development phase.
Finally, Professor Marks (University of Surrey, Guildford) spoke of his experience marketing various antibodies and radioimmunoassays developed in his laboratory. His first business venture had developed out of the usual scientific practice of supplying biological material to others working in the same field as himself. When he realized that the cost in terms of postage and staff time in sending off so many 'free' samples was considerable, he had started to market the material for a fee to cover the costs and to fund further research.
There were a number of other ways in which an academic could be involved with industry. He could act as the inventor/developer of a product or assay, he could sell his expertise as an expert by acting as a consultant to industry, he could use his expert knowledge of a developing field to help him to decide where he should invest his own money in the hope that the field will rapidly expand and produce large profits, or he could act as an entrepreneur himself and develop his own or his students' ideas.
Professor Marks stated that there were problems in all of these options. If a scientist was employed by a university or research council, it was necessary to keep them informed of any such commercial interests, and in some cases they might expect to be involved in sharing any commercial return. The degree of control on such activities exercised by different institutions varied enormously, but with the recent increased Government interest in exploiting ideas, such links were increasingly likely to be tolerated or even actively encouraged.
The meeting was a fascinating journey into the highly complex field of commercial development, its problems and pitfalls, as well as its rewards. The message that came over from most speakers was that exploitation of research needed to be a positive aim, and was unlikely to occur 'by chance'. The need to delay publication until the intellectual property rights were clearly established was antipathetic to most academic mores but essential to any commercial development. Such delays could be particularly difficult for those working on short-term contracts, who would need to publish their results to assist them in obtaining their next grant. The skills needed for the development stages were also clearly different from those needed for research, and therefore the bridging activities of the DTI and research councils were clearly important in aiding development. The need for secrecy that had been stressed seemed slightly at odds with the development of 'clubs' and other cooperative activities, but these were perhaps aimed at the more basic developmental work needed before development of a specific, potentially marketable product.
Although I doubt whether anyone left the meeting feeling that they could now easily proceed to develop one of their research ideas commercially, I think we all came away more aware ofthe difficulties, and also more informed about where to go for advice if we believed we had a marketable product.
Eileen D Rubery Department of Health (The contents of this paper represent the views of the author and in no way commits the Department of Health)
Letters to the Editor
Preference is given to letters commenting on contributions published recently in the JRSM. They should not exceed 400 words and should be typed double-spaced. Rethinking the National Health Service The idea that because the Health Service is free in most of its important aspects, demand will be infinite, originates with the health care economists who live on the periphery ofthe NHS. Mr Harris is quite right to challenge this nihilistic view even though his challenge is politically unpopular (August 1988 JRSM, p487). The amount of organic disease in the country and the amount of treatment that should be made available to the patients is eminently computable and was a fit subject for inclusion in your review of March 1988. Where I do not go along with him is in his light use ofthe word efficiency. Efficiency is necessarily defined only in relation to parameters and it is very rarely evident in any of the expert articles on the subject ofhealth care economics, which parameters are being used. In a health service which has a fixed budget the only index of efficiency we should be using is cost per patient managed or treated. The rest of the efficiency drive merely occupies expensive people and computer time. It is most important that we have models of the pattern of diseases that can be expected and projections of the resources that must be made available to treat them properly. Your conference made it very clear that there is still a tremendous absence of numbers in discussion about health care organization and in fact most ofthese discussions are only concerned with the hospital service which consumes only about a third of the total cost of the NHS in England.
The implications of the fact that the NHS is paid for by a fixed sum have still not been realized. The NHS is not a commercial operation and there are no parallels with commercial operation. The health service is more like a family trying to live on a fixed income than a business. Everyone knows that we should live within our income but the Managers are compelled by the terms of their contract and by
